Jak Inhibitors in African American Patients With Alopecia Areata: A Case Series
April 2025
in “
International Journal of Dermatology
”
TLDR JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
This study examined the response of Black/African American patients with alopecia areata (AA) to JAK inhibitor (JAKi) therapy, involving 16 patients (14 females, 2 males) with a mean age of 29.6 years. The study found a significant reduction in the Severity of Alopecia Tool (SALT) score by 20.1% after JAKi treatment, indicating effective reduction in scalp involvement. Most patients were treated with baricitinib or ritlecitinib, and 63% showed clinical improvement. The study highlights the importance of JAKi in managing AA among Black patients, with over half of the prescriptions covered by insurance, enhancing access to treatment. Limitations include the small sample size and retrospective design, suggesting the need for further research to explore racial differences in treatment response and to guide early intervention strategies.